Pfizer Investor Presentation — March 2019

Document content

Cowen and Company Healthcare Conference:

Global President & General

Manager, Pfizer Oncology Chris Boshoff, M.D., Ph.D.,

Chief Development Officer, Oncology, Pfizer Global Product Development

March 12, 2019 │ 2

Forward Looking Statements

This presentation may include forward -looking statements about, among other things, Pfizer’s oncology in -

line products and product candidates, including anticipated regulatory submissions, data read -outs, study

starts, approvals, performance and potential benefits of Pfizer's oncology products and product candidates,

that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

Additional information regarding these factors can be found in Pfizer’s Annual Report on Form 10 -K for the

fiscal year ended December 31, 2018 and in our subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward -Looking Information and Factors that May Affect Future

Results”, as well as in our subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission (SEC) and available at www.sec.gov and www.pfizer.com.

The forward -looking statements in this presentation speak only as of the original date of this presentation,

and we undertake no obligation to update or revise any of these statements.

Continued Growth and Commitment to Oncology

Advancing Our Leadership

medicines & biosimilars 18

% of Pfizer investment in

R&D goes to Oncology > 10K